TriNutra receives Thailand FDA novel food approval for its proprietary and standardised black seed oil

Published: 30-Oct-2023

TriNutra, the supplier of the first cold-pressed Nigella sativa oil standardised to 3% thymoquinone with low free fatty acids (<1.25%), has announced that its ingredient ThymoQuin now has the Thailand Food and Drug Administration (TFDA) approval as a novel food to be sold in dietary supplements in the region

TriNutra’s proprietary black seed oil, branded ThymoQuin, had to pass the standards of the Thai Ministry of Public Health as a novel food for supplements and show its quality and stability to comply with the ministry’s quality standards.

“We are incredibly proud to reveal this achievement in Thailand,” said Morris Zelkah, CEO of TriNutra.

“The sales and awareness of black seed oil continue to grow and with our exclusive Thailand distribution partner, Aumento Chemical Ltd, we can now offer our clinically studied, high quality, potent and bioavailable black seed oil to Thai residents.”

The TFDA was established under the Ministry of Public Health to protect public health and consumer rights. It oversees the manufacturing, import and distribution of regulated products to ensure they comply with strict safety and quality standards.  

“ThymoQuin offers the highest quality black seed oil with clinically validated health benefits,” said Mrs Watcharee Saponowong, Managing Director of Aumento Chemical.

Like this story? Subscribe to Nutraceutical Business Review magazine for incisive analysis, the latest news and expert-written articles from the functional food and drink industries. For more information click here.

“We are happy to provide this powerful ingredient to our Thailand residents for improved health and well-being. We have the TFDA registration numbers and welcome customers to contact us for more information.” 

TriNutra’s proprietary black seed oil is naturally standardised to 3% thymoquinone, the key bioactive, with very low free fatty acids (below 1.25%).

This USP-grade, full-spectrum composition has been clinically tested to support a balanced inflammatory response, improve mitochondrial activity, including ATP production and deliver excellent antioxidant activity and antimicrobial effects.

ThymoQuin is currently available in multiple continents and countries including, but not limited to, North America, Europe and APAC.

You may also like